24 Result(s)

Chapter

Effects of Treatment of Malignant Lymphomas on the Granulocytic Progenitor Cells (CFU_c)

Study of the after-effects of therapy on the healthy organs is one of the main preoccupations of oncology. Although progress in therapeutics has clearly improved the prognosis for malignant lymphomas, the afte...

C. Parmentier, D. Maraninchi, N. Morardet, J. P. Droz… in Lymphoid Neoplasias II (1978)

Chapter

First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors

Trials of active nonspecific immunotherapy as adjuvant therapy for tumors have increased dramatically in number since the results that have been published on acute leukemia [6] and melanoma [3, 5, 7–9]. In spi...

J. L. Amiel, H. Sancho-Garnier… in Adjuvant Therapies and Markers of Post-Sur… (1979)

Chapter

Post-Radiotherapy Adjuvant Chemotherapy of Regionally Advanced UNPC: Increase in Disease Free Survival

38 patients with NPC, most of them from North Africa and South of Italy, with histo and serological diagnosis of UNPC (undifferentiated nasopharyngeal carcinoma), seen from January ‘83 till December ’84 at the In...

C. Domenge, J. L. Marin, J. P. Droz, F. Eschwege… in Epstein-Barr Virus and Human Disease (1987)

Chapter and Conference Paper

High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors

Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...

J. L. Pico, J. P. Droz, E. Zambon… in Proceedings of the 3rd International Congr… (1991)

Article

Phase II trial of pirarubicin in the treatment of advanced bladder cancer

Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclini...

M. Mahjoubi, J. Kattan, M. Ghosn, J. -P. Droz, I. Philippot… in Investigational New Drugs (1992)

Chapter and Conference Paper

No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...

H. Curé, J. P. Droz, J. L. Pico, P. Biron, P. Kerbrat… in Cancer Treatment An Update (1994)

Article

Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

 Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...

C. Maulard, J. P. Droz, D. Jessueld, M. Housset… in Cancer Chemotherapy and Pharmacology (1995)

Article

Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...

C. Maulard, P. Richaud, J. P. Droz, D. Jessueld… in Cancer Chemotherapy and Pharmacology (1995)

Chapter

Testicular tumors

Tumors of the testicles, although relatively infrequent (less than 1% of cancers in males), are still used as a model for study in oncology, principally as a result of their curability by chemotherapy.

E.-Ch. Antoine, J.-P. Droz, D. Buthiau in CT and MRI in Oncology (1998)

Article

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...

M.J.A. de Jonge, J.P. Droz, L. Paz-Ares, A.T. van Oosterom… in Investigational New Drugs (2004)

Chapter

Traitement des formes de mauvais pronostic

A. Fléchon, J.-P. Droz in Cancer du testicule (2006)

Chapter

Biologie des tumeurs germinales

A. Flèchon, J.-P. Droz in Les cancers ovariens (2006)

Article

Réflexions sur l’organisation de l’oncogériatrie et rôle des réseaux

Le réseau d’oncogériatrie devra comprendre toutes les personnes et toutes les structures qui gèrent la prise en charge clinique de la personne âgée atteinte de cancer à toutes les étapes de la maladie. Les out...

J.-P. Droz, P. Courpron in Oncologie (2006)

Article

Quelle évaluation gérontologique faut-il utiliser pour les essais multicentriques?

Peu de personnes âgées atteintes de cancer sont incluses dans des essais cliniques. Ainsi, la connaissance sur l’efficacité et la tolérance des traitements est-elle médiocre dans cette population de patients. ...

A. Chaladaj, C. Terret, G. Albrand, P. Courpron, J. -P. Droz in Oncologie (2007)

Article

Motesanib difosfato nel cancro tiroideo differenziato progressivo

PREMESSE: L’espressione del vascular endothelial growth factor (VEGF) è tipica dei carcinomi tiroidei differenziati ed è associata ad un comportamento aggressivo e ad una evoluzione sfavorevole. Il motesanib difo...

S. I. Sherman, L. J. Wirth, J. P. Droz, M. Hofmann, L. Bastholt… in L’Endocrinologo (2008)

Chapter

Rénaux

Le concept de glomérulopathie paranéoplasique a été initialement évoqué par Galloway en 1922, avec l’association d’une maladie de Hodgkin et d’un syndrome néphrotique (1). Après cette pre...

J. Bacchetta, L. Juillard, P. Cochat, J.-P. Droz in Tumeurs malignes rares (2010)

Chapter

Localisation uro-génitale

Les sarcomes urogénitaux de l’adulte sont des tumeurs rares représentant moins de 2% des tumeurs urogénitales (1). L’équipe du Memorial Sloan- Kettering a publié son expérience sur 131 pa...

H. Boyle, C. Chevreau, J.-P. Droz in Tumeurs malignes rares (2010)